

Figure S1. Structure of JP11646 or (1*r*,4*r*)-N1-(4-((*Z*)-(2,4-dioxothiazolidin-5-ylidene)methyl)pyrimidin-2-yl)-N4-(naphthalen-1-ylmethyl)cyclohexane-1,4-diaminium; or (*Z*)-5-(2-(((1*r*,4*r*)-4-((naphthalen-1-ylmethyl)amino)cyclohexyl)amino)pyrimidin-4-yl)methylene)thiazolidine-2,4-dione dihydrochloride.




Figure S2. PIM2 expression levels in various solid cancer cell lines in the CCLE dataset. PIM2, proviral integration of Moloney virus 2.




Figure S3. Viability of MDA-MB-231 cells treated with/without 1 nM bortezomib for 12 h followed by treatment with 100 nM JP11646 for 72 h. Bor, bortezomib; JP, JP11646.

